Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy

Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification

(2019) Charlotte Hedskog et al.   Open Forum Infectious Diseases

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

(2019) Thomas G Cotter et al.   Drug Design Development and Therapy

OUP accepted manuscript

(2018)   CLINICAL INFECTIOUS DISEASES

Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018

(2018) Maria C. Sorbo et al.   DRUG RESISTANCE UPDATES

An update on the toxicological considerations for protease inhibitors used for hepatitis C infection

(2018) Lung-Yi Mak et al.   Expert Opinion on Drug Metabolism & Toxicology

Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study

(2018) Jia-Horng Kao et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

EASL Recommendations on Treatment of Hepatitis C 2018

(2018) Jean-Michel Pawlotsky et al.   JOURNAL OF HEPATOLOGY

Danoprevir: First Global Approval

(2018) Anthony Markham et al.   DRUGS

Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C

(2018) Antonio Rivero-Juarez et al.   Expert Opinion on Drug Metabolism & Toxicology

Chinese approval for Ascletis' HCV drug is first homegrown success

(2018) Shannon Ellis   NATURE BIOTECHNOLOGY

Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease

(2018) Ashley N. Matthew et al.   STRUCTURE

APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?

(2018) Tatsuo Kanda et al.   Hepatology International

Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection

(2017) Yoshiki Koizumi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution

(2017) Yu Zhang et al.   Virology Journal

Hepatitis C virus genotypes and subtypes circulating in Mainland China

(2017) Ying Chen et al.   Emerging Microbes & Infections

Approved Antiviral Drugs over the Past 50 Years

(2016) Erik De Clercq et al.   CLINICAL MICROBIOLOGY REVIEWS

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis

(2016) Edward J. Gane et al.   Hepatology International

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

(2016) Graham R. Foster et al.   JOURNAL OF HEPATOLOGY

Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease

(2016) Djadé I. Soumana et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China

(2016) Kali Zhou et al.   PLoS One

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin

(2015) Jordan J. Feld et al.   JOURNAL OF HEPATOLOGY

C-Nucleosides To Be Revisited

(2015) Erik De Clercq   JOURNAL OF MEDICINAL CHEMISTRY

Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace

(2015) Erik De Clercq   REVIEWS IN MEDICAL VIROLOGY

Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1–6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance

(2015) Lize Cuypers et al.   Viruses-Basel

Effect of drug-resistance mutations on antiviral agents in HCV patients

(2014) Grey Liu et al.   ANTIVIRAL THERAPY

Current race in the development of DAAs (direct-acting antivirals) against HCV

(2014) Erik De Clercq   BIOCHEMICAL PHARMACOLOGY

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

(2014) Barbara J. Brennan et al.   CLINICAL PHARMACOKINETICS

Identification of Weak Points of Hepatitis C Virus NS3 Protease Inhibitors Using Surface Plasmon Resonance Biosensor-Based Interaction Kinetic Analysis and Genetic Variants

(2014) Sofia Svahn Gustafsson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study

(2014) Edward J. Gane et al.   LIVER INTERNATIONAL

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4

(2014) Gregory Everson et al.   LIVER INTERNATIONAL

A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations

(2014) Bryan C. Dickinson et al.   Nature Communications

Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance

(2013) Akbar Ali et al.   ACS Chemical Biology

Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders

(2013) Edward J. Gane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a

(2013) Navaneethan Palanisamy et al.   ANTIVIRAL RESEARCH

Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection

(2013) Huiying Rao et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

(2013) Yutong Jiang et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

(2012) Keith P. Romano et al.   PLoS Pathogens

Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution

(2011) Sharlene R. Lim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)

(2011) Ingrid Imhof et al.   HEPATOLOGY

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients

(2011) Edward J. Gane et al.   JOURNAL OF HEPATOLOGY

In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

(2010) O. Lenz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

(2010) K. P. Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior

(2009) Ravi Rajagopalan et al.   BIOCHEMISTRY

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

(2009) David L. Thomas et al.   NATURE

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

(2008) S. D. Seiwert et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY